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REVIEW
Abstract: Daptomycin is a novel bactericidal antibiotic with excellent activity against gram-
positive organisms. It is a large cyclic lipopeptide with a unique mechanism of action.
Daptomycin is given once a day and is renally cleared, requiring dose adjustment in patients
with impaired renal function. Unfortunately, there have been case reports of resistant gram-
positive organisms. Daptomycin is generally well tolerated, though myopathy has been
reported. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors should
be stopped in patients on daptomycin. Daptomycin shows promise in experimental models of
endocarditis, meningitis, ventriculitis, and peritonitis, and is currently approved for use in
skin and soft-tissue infections. Daptomycin is a welcome newcomer to the gram-positive
antimicrobial arsenal.
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Introduction
With the increasing numbers and types of resistant organisms, there is an increasing
need for antibiotics to treat infections caused by them. Daptomycin is a cyclic
lipopeptide with a broad spectrum of activity against gram-positive organisms, both
aerobic and anaerobic. This includes resistant strains as well such as methicillin-
resistant Staphylococcus aureus (MRSA), glycopepetide-intermediate Staphylococcus
aureus (GISA), vancomycin-resistant enterococci (VRE), coagulase-negative
staphylococci (CoNS), and penicillin-resistant Streptococcus pneumoniae (PRSP).
Daptomycin was discovered in the early 1980s, at Eli Lilly and Company (Tally
and DeBruin 2000). Daptomycin was initially developed in the late 1980s and early
1990s but was ultimately shelved due to concerns regarding adverse effects, in
particular drug-induced myopathy. Cubist Pharmaceuticals Inc. licensed worldwide
rights from Eli Lilly and Company in 1997 (Tally and DeBruin 2000).
Basics/mechanism of action
Daptomycin is derived as a fermentation product from Streptomyces roseospours.
The unique structure of daptomycin consists of a 13-member amino acid cyclic
lipopeptide with a decanoyl side-chain (Steenbergen et al 2005) (Figure 1).
Daptomycin molecular weight is 1620.67 (Cubicin package insert 2003). This is a
rather large molecule which may influence its distribution into tissues.
The exact details of daptomycin’s mechanism of action are not completely
understood. It is believed to have a unique mechanism of action that involves calcium-
dependent insertion of the lipophilic daptomycin tail into the bacterial cell membrane,
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causing rapid depolarization and potassium ion efflux
(Steenbergen et al 2005) (Figure 2). It has been observed
that daptomycin causes a calcium-dependent dissipation of
the membrane potential (∆ psi) in Staphylococcus aureus
without noticeably affecting the chemical gradient (∆ pH)
across the membrane (Alborn et al 1991). This unique
mechanism of action makes daptomycin rapidly bactericidal.
Pharmacokinetics
Daptomycin exhibits linear pharmacokinetics across a wide
range of doses with once daily dosing up to 6 mg/kg (Figure
3) (Woodworth et al 1992; Dvorchik et al 2003).
Daptomycin doses of 8 mg/kg exhibit a slight nonlinearity
(Dvorchik et al 2003).
Approximately 92% of daptomycin is protein-bound
(Woodworth et al 1992). Excretion of the drug occurs
primarily via the kidney with approximately 80% of the total
dose, of which two-thirds is intact drug, recovered in the
urine (Tally and DeBruin 2000). Due to daptomycin’s
predominant renal clearance, it requires dose adjustments
in those with impaired renal function. Daptomycin clearance
in females is estimated to be approximately 80% that of
males with similar renal function, although this has
otherwise not been shown to be statistically or clinically
significant (Dvorchik et al 2004).
The observed t½ is relatively long (~9 hours) (Dvorchik
et al 2003). The long t½ allows for once daily dosing in
patients with normal renal function. Daptomycin t½ is
increased by 2.3-fold in patients with creatnine clearance
(CLcr) <40 mL/min and 3.5-fold in patients on dialysis
(Dvorchik et al 2004).
Daptomycin remains in the plasma and interstitial fluid
and therefore has a small volume of distribution (Dvorchik
et al 2003, 2004).
The maximum serum concentration after escalating
single daily doses of daptomycin ranged from approximately
55, 85 to 95 µg/mL, and 115 to 130 µg/mL with doses of 4,
6, and 8 mg/kg, respectively (Dvorchik et al 2003). The area
under the curve following doses of 4, 6, and 8 mg/kg/day
revealed similar linearity to the Cmax pharmacokinetic data
above (Dvorchik et al 2003, 2004).
Daptomycin has been shown to exhibit a post-antibiotic
effect (PAE) on Staphylococcus aureus and Streptococcus
pneumoniae (Pankuck et al 2003; Safdar et al 2004). The
PAE combined with the long t½ of daptomycin allows for
once daily dosing in patients with normal renal function.
Daptomycin should not be used to treat pneumonia. This
is due to the fact that daptomycin is inhibited by surfactant
(Silverman et al 2005).
Spectrum of activity
 As mentioned before, daptomycin has a broad spectrum of
activity against gram-positive organisms, both aerobic and
anaerobic. This includes resistant strains as well such as
MRSA, GISA, VRE, CoNS, and PRSP. Calcium
concentration of the media is an important factor in
interpreting susceptibility testing (Fuchs et al 2000). The
manufacturer recommends susceptibility testing with broth
microdilution using Mueller-Hinton broth adjusted to a
calcium content of 50 mg/L (Cubicin package insert 2003).
Below are the minimum inhibitory concentration of anti-
infective needed to inhibit the growth of 90% of strains
Figure 1 Structure of daptomycin. Copyright © 2005. Reproduced with permission from Steenbergen JN, Alder J, Thorne GM, et al. 2005. Daptomycin: a lipopeptide
antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother, 55:283–8.Therapeutics and Clinical Risk Management 2006:2(2) 171
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(MIC90s) of a variety of gram-positive organisms from
various in vitro studies:
• Staphylococcus aureus* MIC 0.5 mg/L (Streit et al 2004)
(*without a breakdown into MSSA and MRSA).
• MSSA MIC 0.25 to 0.5 mg/L (Wise et al 2001; Fuchs et
al 2002; Richter et al 2003).
• MRSA MIC 0.5 to 1.0 mg/L (Wise et al 2001; Fuchs et
al 2002; Richter et al 2003).
• GISA MIC 0.125–0.5 mg/L (Akins and Rybak 2000,
2001). No differences were seen for susceptibility of
vanA, vanB1, and vanD strains (Jevitt et al 2003).
• VRSA: Daptomycin was found to be bactericidal against
a VRSA (strain HMC3) isolated in Pennsylvania, US
that was resistant to vancomycin through the presence
of the vanA resistance gene; it also contained mecA,
erm(A), erm(B), tet(K) and aac(6')-aph(2″), conferring
resistance to
 licensed ß-lactams, macrolides, tetracycline
and aminoglycosides (Bozdogan et al 2003).
• CoNS 0.5 mg/L (Wise et al 2001; Fuchs et al 2002; Sader
et al 2004; Streit et al 2004).
• Enterococcus fecalis** MIC 1 to 2 mg/L (Wise et al
2001; Richter et al 2003; Streit et al 2004)
(**Enterococci were defined as vancomycin susceptible
and those not further defined. If known to be VRE then
stated as such).
• Vancomycin-resistant Enterococcus fecalis MIC 1 to
4 mg/L (Richter et al 2003; Sader et al 2004).
• Enterococcus faecium MIC 2 to 4 mg/L (Wise et al 2001;
Richter et al 2003; Streit et al 2004).
• Vancomycin-resistant Enterococcus faecium MIC 2 to
4 mg/L (Richter et al 2003; Sader et al 2004).
• Streptococcus pneumoniae MIC 0.25 mg/L (Wise et al
2001; Streit et al 2004).
• PRSP MIC 0.25 mg/L (Sader et al 2004).
Susceptibility breakpoints for as set forth by the Food
and Drug Administration (FDA), which are the same as those
from the National Committee for Clinical Laboratory
Standards, are as follows (Cubicin package insert 2003;
Streit et al 2005):
• Staphylococcus aureus (MSSA and MRSA) <1 mg/L
• Streptococcus spp. (S. pyogenes, S. agalactiae, and S.
dysgalactiae subsp. equisimilis) ≤1 mg/L
• Enterococcus fecalis (vancomycin-susceptible only)
<4 mg/L
Resistance
There appears to be a low rate of spontaneous resistance to
daptomycin with limited increases in MIC and relative ease
of treatment of resistant isolates (Silverman et al 2001).
Population analysis of three Staphylococcus aureus
isolates for which the daptomycin MICs were 8 mg/mL
showed a pattern of homogeneous resistance (Jevitt et al
2003).
There have been multiple case reports of gram-positive
organisms with daptomycin resistance, these include MRSA
(Mangili et al 2005), Enterococcus faecium (Sabol et al
2005; Long et al 2005), and Enterococcus fecalis (Munoz-
Price et al 2005).
Adverse drug reactions
Early in clinical trials daptomycin was found to have skeletal
muscle effects that included myopathy with muscle
weakness and elevated serum creatine phosphokinase
(CPK). Further testing using a dog model revealed that this
was more of a problem with fractioned dosing that could be
overcome by changing the dosing schedule to once daily
from every twelve hours (Oleson et al 2000).
Figure 2 Proposed mechanism of action of daptomycin. Hypothetical steps: step 1, daptomycin binds to the cytoplasmic membrane in a calcium-dependent manner;
step 2, daptomycin oligomerizes, disrupting the membrane; step 3, the release of intracellular ions and rapid cell death. Copyright © 2005. Reproduced with
permission from Steenbergen JN, Alder J, Thorne GM, et al. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
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Daptomycin is generally well tolerated (Dvorchik et al
2003; Arbeit et al 2004). A large randomized trial evaluating
the safety and efficacy of daptomycin for the treatment of
complicated skin and skin-structure infections (cSSSI)
involving 1092 patients revealed the frequency, distribution,
and severity of adverse events to be similar for daptomycin
and standard therapy (Arbeit et al 2004) (Table 1).
There was a case report of significant myopathy with
daptomycin without pronounced CPK elevation (CPK
<500 U/L) at a dose of 6 mg/kg intravenously per day
(Veligandla et al 2004). There has also been a case report of
myopathy and possible hepatotoxicity in a patient with
underlying chronic liver disease, but the elevations in the
transaminases were mild (aspartase aminotransferase 239 U/
L and alanine aminotransferase 48 U/L) (Echevarria et al
2005). It is recommended by the manufacturer that in
patients with unexplained signs and symptoms of myopathy
in conjunction with CPK elevation >1000 U/L, or in patients
without reported symptoms who have marked elevation in
CPK (≥10x ULN), daptomycin should be discontinued
(Cubicin package insert 2003).
Drug–drug interactions
Daptomycin is without any known significant drug–drug
interactions. Nonetheless, the manufacturer recommends
giving consideration to temporarily discontinuing use of
HMG CoA reductase inhibitors while patients receive
daptomycin (Cubicin package insert 2003). This is
recommended due to the potential confusion that may arise
if a patient on an HMG CoA reductase inhibitor were to
experience myopathy or an increase in CPK level.
Clinical uses
Daptomycin is currently only approved for the treatment of
cSSSI caused by susceptible Staphylococcus aureus (MSSA
and MRSA), Streptococcus spp. (S. pyogenes, S. agalactiae,
and S. dysgalactiae subsp. equisimilis), and Enterococcus
fecalis (vancomycin-susceptible only) (Cubicin package
insert 2003; Arbeit et al 2004). This includes diabetic foot
ulcers (Arbeit et al 2004; Lipsky and Stoutenburgh 2005).
Daptomycin has proven to be effect in multiple
experimental endocarditis models. In a retrospective analysis
of 49 patients with endocarditis due to gram-positive
organisms, daptomycin dosed at >6 mg/kg intravenously
every 24 hours showed high cure rates (Levine and Lamp
2005).
There have also been case reports of successful treatment
of prosthetic valve endocarditis in humans (Mohan et al
2005). Daptomycin trials in human endocarditis are currently
in progress.
In an experimental animal (rabbit) model of meningitis
due to penicillin- and quinolone-resistant Streptococcus
pneumoniae, daptomycin looked promising when compared
with the combination of ceftriaxone and vancomycin
(Cottagnoud et al 2004).
In an experimental model of Staphylococcus aureus
ventriculitis in hydrocephalic rabbits, daptomycin was
detectable in the periventricular white matter but in amounts
too small to quantitate. Daptomycin killed more
Staphylococcus aureus more rapidly than vancomycin in
this model (Haworth et al 1990).
Daptomycin also appears to be a promising for the
treatment of peritoneal dialysis-associated peritonitis due
to staphylococci and streptococci in an in vitro peritoneal
dialysate model (Hermsen et al 2003).
A trend toward equivalent efficacy between intravenous
daptomycin and intravenous ciprofloxacin was observed in
the treatment of gram-positive urinary tract infections in
which Enterococcus faecalis and Staphylococcus aureus
were the most common gram-positive pathogens (Naber et
al 2004). Based on the previously mentioned susceptibilities
and the fact that daptomycin is predominately renally
excreted, one would predict that daptomycin should be
Figure 3 Linearity of dose versus area under the curve (AUC). Copyright ©
1992. Reproduced with permission from Woodworth JR, Nyhart EH, Brier GL,
et al. 1992. Single-dose pharmacokinetics and antibacterial activity of
daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents
Chemother, 36:318–25.Therapeutics and Clinical Risk Management 2006:2(2) 173
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effective in the treatment of urinary tract infections due to
such pathogens, but this warrants further studies.
Daptomycin was at least equivalent to vancomycin
against chronic foreign body infections due to
Staphylococcus aureus, though vancomycin has poor
activity in these infections. In a prospective study of
daptomycin in the treatment of prosthetic joint infections, 5
of 7 patients with MRSA infections experienced treatment
failures, so the efficacy of daptomycin in the treatment of
prosthetic joint infections is uncertain (Rao and David 2005).
Daptomycin should not be used to treat pneumonia. This
is due to the fact that daptomycin is inhibited by surfactant
(Silverman et al 2005).
Dose
The dose of daptomycin is 4 mg/kg intravenously every 24
hours for patients with normal renal function (Cubicin
package insert 2003; Arbeit et al 2004). For patients with a
creatinine clearance of less than 30 mg/min, including those
patients on hemodialysis, continuous ambulatory peritoneal
dialysis, or continuous renal replacement therapy (CRRT)
which includes continuous arteriovenous
 hemofiltration
(CAVH), continuous venovenous
 hemofiltration (CVVH),
continuous arteriovenous
 hemodialysis (CAVHD),
continuous venovenous
 hemodialysis (CVVHD), and
continuous
 venovenous hemodialfiltration (CVVHDF), the
dose is 4 mg/kg intravenously every 48 hours (Cubicin
package insert 2003; Arbeit et al 2004; Trotman et al 2005).
Patients with moderate hepatic impairment receiving
daptomycin do not require an adjustment in daptomycin dose
or dose regimen (Dvorchik 2004). No adjustment in
daptomycin dose or dose regimen should be required
 based
solely on obesity (Dvorchik and Damphousse 2005). An
international, multicenter, randomized open label trial using
the off-label dose of daptomycin at 6 mg/kg every 24 hours
showed that this dose was similar in efficacy to standard
therapy for Staphylococcus aureus bacteremia and
endocarditis (Fowler et al 2005).
Conclusion
Daptomycin is a cyclic lipopeptide antibiotic with excellent
activity against gram-positive organisms. Although there
have been case reports of daptomycin-resistant gram-
positive organisms, it has a unique mechanism of action
that renders it bactericidal. Daptomycin is given once a day
and is renally cleared, requiring dose adjustment in patients
with impaired renal function. Daptomycin is generally well
tolerated, though myopathy has been reported. Daptomycin
is currently approved for use in skin and soft-tissue
infections and shows promise in experimental models of
endocarditis, meningitis, ventriculitis, and peritonitis.
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